Enfortumab vedotin Approval Status
FDA Approved: No
Generic name: enfortumab vedotin
Company: Astellas and Seattle Genetics
Treatment for: Urothelial Carcinoma
Enfortumab vedotin is a Nectin-4 targeted antibody-drug conjugate (ADC) in development for the treatment of patients with locally advanced or metastatic urothelial cancer.
Development Status and FDA Approval Process for enfortumab vedotin
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.